The Industry's foremost leader of antivenom technologies:
  • RDT
  • //
  • Rare Disease Therapeutics, Inc.

Intended for US Healthcare Professionals Only

ANASCORP® is the only FDA approved treatment for patients with clinical signs of scorpion envenomation.1

1ANASCORP [centruroides (scorpion) immune F(ab’)2 (equine)] injection Prescribing Information. Rare Disease Therapeutics, Inc.; Franklin, TN. June 2021.

Anascorp®
Brochure

  • (Download PDF)

Anascorp®
Package Insert

  • (Download PDF)

Anascorp®
Video 

  • (Medical Professionals Only)

Anascorp®
Return Policy

  • (Download PDF)

INDICATION

ANASCORP is an antivenom indicated for treatment of clinical signs of scorpion envenomation.

CONTRAINDICATIONS

None.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Severe hypersensitivity reactions, including anaphylaxis, are possible with ANASCORP. Prepare for monitoring and management of allergic reactions, particularly in patients with a history of hypersensitivity to equine (horse) proteins or patients who have received previous therapy with antivenoms containing equine proteins.

Delayed Allergic Reactions (Serum Sickness)

Delayed allergic reactions (serum sickness) may occur following treatment with ANASCORP. Patient monitoring with a follow-up visit is recommended.

Transmissible Infectious Agents

ANASCORP is made from equine plasma and may contain infectious agents, e.g. viruses.

Reaction to Cresol

Localized reactions and generalized myalgias have been reported with the use of cresol as an injectable excipient.

ADVERSE REACTIONS

The most common adverse reactions observed in ≥ 2% of patients in the clinical studies for ANASCORP were: vomiting, pyrexia, rash, nausea, and pruritus.

Postmarketing Experience

The following adverse reactions have been identified during post approval use of Anascorp: chest tightness, palpitations, rash and pruritus.

 

See Full Prescribing Information